481 related articles for article (PubMed ID: 34520702)
1. Opioid treatment programs, telemedicine and COVID-19: A scoping review.
Chan B; Bougatsos C; Priest KC; McCarty D; Grusing S; Chou R
Subst Abus; 2022; 43(1):539-546. PubMed ID: 34520702
[No Abstract] [Full Text] [Related]
2. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
Nunes EV; Levin FR; Reilly MP; El-Bassel N
J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
[TBL] [Abstract][Full Text] [Related]
3. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
4. Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis.
Priest KC; King CA; Englander H; Lovejoy TI; McCarty D
Subst Abus; 2022; 43(1):1251-1259. PubMed ID: 35670778
[No Abstract] [Full Text] [Related]
5. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
[TBL] [Abstract][Full Text] [Related]
6. Assessing the impact of social distancing measures implemented during COVID-19 pandemic on medications for opioid use disorder in West Virginia.
Haggerty T; Khodaverdi M; Dekeseredy P; Wood N; Hendricks B; Peklinsky J; Sedney CL
J Subst Abuse Treat; 2022 May; 136():108687. PubMed ID: 34903397
[TBL] [Abstract][Full Text] [Related]
7. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
Pilarinos A; Bromberg DJ; Karamouzian M
JAMA Pediatr; 2022 Mar; 176(3):304-311. PubMed ID: 34870707
[TBL] [Abstract][Full Text] [Related]
8. Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.
Eugenia Socias M; Choi JC; Fairbairn N; Johnson C; Wilson D; Debeck K; Brar R; Hayashi K
Int J Drug Policy; 2023 Aug; 118():104075. PubMed ID: 37271070
[TBL] [Abstract][Full Text] [Related]
9. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
[TBL] [Abstract][Full Text] [Related]
10. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
[TBL] [Abstract][Full Text] [Related]
11. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review.
Krawczyk N; Fawole A; Yang J; Tofighi B
Addict Sci Clin Pract; 2021 Nov; 16(1):68. PubMed ID: 34774106
[TBL] [Abstract][Full Text] [Related]
12. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
[TBL] [Abstract][Full Text] [Related]
13. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
Hammerslag LR; Mack A; Chandler RK; Fanucchi LC; Feaster DJ; LaRochelle MR; Lofwall MR; Nau M; Villani J; Walsh SL; Westgate PM; Slavova S; Talbert JC
JAMA Netw Open; 2023 Oct; 6(10):e2336914. PubMed ID: 37851446
[TBL] [Abstract][Full Text] [Related]
14. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.
Frost MC; Lampert H; Tsui JI; Iles-Shih MD; Williams EC
Addict Sci Clin Pract; 2021 Oct; 16(1):62. PubMed ID: 34635170
[TBL] [Abstract][Full Text] [Related]
15. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B
J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447
[TBL] [Abstract][Full Text] [Related]
16. Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.
Degenhardt L; Clark B; Macpherson G; Leppan O; Nielsen S; Zahra E; Larance B; Kimber J; Martino-Burke D; Hickman M; Farrell M
Lancet Psychiatry; 2023 Jun; 10(6):386-402. PubMed ID: 37167985
[TBL] [Abstract][Full Text] [Related]
17. A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome.
Sujan A; Cleary E; Douglas E; Aujla R; Boyars L; Smith C; Guille C
Fam Pract; 2022 Mar; 39(2):311-315. PubMed ID: 34537839
[TBL] [Abstract][Full Text] [Related]
18. Unprecedented need and recommendations for harnessing data to guide future policy and practice for opioid use disorder treatment following COVID-19.
Livingston NA; Ameral V; Banducci AN; Weisberg RB
J Subst Abuse Treat; 2021 Mar; 122():108222. PubMed ID: 33303255
[TBL] [Abstract][Full Text] [Related]
19. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
Pena E; Ahmed S
Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
[No Abstract] [Full Text] [Related]
20. COVID-19 and treating incarcerated populations for opioid use disorder.
Donelan CJ; Hayes E; Potee RA; Schwartz L; Evans EA
J Subst Abuse Treat; 2021 May; 124():108216. PubMed ID: 33288348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
